The U.S. Food and Drug Administration today approved Admelog (Insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. Admelog is the first short-acting insulin approved as a “follow-on” product (Submitted through the agency’s 505(B)(2) pathway). Source 6k.